title: XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
abstract: P-glycoprotein (Pgp) and XIAP co-expression has been discussed in the process of the acquisition of multidrug resistance (MDR) in cancer. Here, we evaluated XIAP and Pgp expression in chronic myeloid leukemia (CML) samples, showing a positive correlation between them. Furthermore, we evaluated the effects of imatinib in XIAP and Pgp expression using CML cell lines K562 (Pgp(-)) and K562-Lucena (Pgp(+)). Imatinib increased XIAP and Pgp expression in K562-Lucena cells, while in K562 cells a downregulation of these proteins was observed, suggesting that imatinib induces an increment of MDR phenotype of CML cells that previously exhibit high levels of Pgp/XIAP co-expression.
authors.affiliation: Laboratório de Hemato-Oncologia Celular e Molecular, Programa de Hemato-Oncologia Molecular, Coordenação Geral Técnico-Científica, Instituto Nacional de Câncer and Programa de Pós-Graduação em Oncologia/INCA, Brazil.
authors.forename: Karina Lani
authors.initials: KL
authors.lastname: Silva
authors.forename: Paloma Silva
authors.initials: PS
authors.lastname: de Souza
authors.forename: Gabriela
authors.initials: G
authors.lastname: Nestal de Moraes
authors.forename: Arthur
authors.initials: A
authors.lastname: Moellmann-Coelho
authors.forename: Flavia da Cunha
authors.initials: Fda C
authors.lastname: Vasconcelos
authors.forename: Raquel Ciuvalschi
authors.initials: RC
authors.lastname: Maia
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics* / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D001549:Benzamides / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002648:Child; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D055785:Gene Knockdown Techniques; D006801:Humans; D000068877:Imatinib Mesylate; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics / Q000378:metabolism; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology*; D034622:RNA Interference; D000077022:Survivin; D051636:X-Linked Inhibitor of Apoptosis Protein / Q000235:genetics* / Q000378:metabolism; D055815:Young Adult
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D001549:Benzamides; D051034:Inhibitor of Apoptosis Proteins; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000077022:Survivin; D051636:X-Linked Inhibitor of Apoptosis Protein; D000068877:Imatinib Mesylate
keywords: CML; CSA; Chronic myeloid leukemia; IAPs; IC(50); Imatinib; MDR; MFI; Multidrug resistance; P-glycoprotein; Pgp; RFI; Rho-123; Survivin; VRP; XIAP; chronic myeloid leukemia; concentration achieving 50% inhibition of cell growth; cyclosporin A; inhibitor of apoptosis proteins; mean of fluorescence intensity; multidrug resistance; ratio of mean of fluorescence intensity; rhodamine-123; verapamil